Switch theme
Sign up to access all valuation multiples
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
2020
110
LTM Revenue $35.8M
LTM EBITDA -$23.3M
$214M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TriSalus Life Sciences has a last 12-month revenue (LTM) of $35.8M and a last 12-month EBITDA of -$23.3M.
In the most recent fiscal year, TriSalus Life Sciences achieved revenue of $29.4M and an EBITDA of -$26.2M.
TriSalus Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TriSalus Life Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $35.8M | XXX | $29.4M | XXX | XXX | XXX |
| Gross Profit | $30.9M | XXX | $25.3M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$23.3M | XXX | -$26.2M | XXX | XXX | XXX |
| EBITDA Margin | -65% | XXX | -89% | XXX | XXX | XXX |
| EBIT | -$29.6M | XXX | -$36.2M | XXX | XXX | XXX |
| EBIT Margin | -83% | XXX | -123% | XXX | XXX | XXX |
| Net Profit | -$30.9M | XXX | -$30.0M | XXX | XXX | XXX |
| Net Margin | -86% | XXX | -102% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $13.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TriSalus Life Sciences's stock price is $5.
TriSalus Life Sciences has current market cap of $194M, and EV of $214M.
See TriSalus Life Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $214M | $194M | XXX | XXX | XXX | XXX | $-1.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TriSalus Life Sciences has market cap of $194M and EV of $214M.
TriSalus Life Sciences's trades at 7.3x EV/Revenue multiple, and -8.2x EV/EBITDA.
Equity research analysts estimate TriSalus Life Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TriSalus Life Sciences has a P/E ratio of -6.3x.
See valuation multiples for TriSalus Life Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $194M | XXX | $194M | XXX | XXX | XXX |
| EV (current) | $214M | XXX | $214M | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 7.3x | XXX | XXX | XXX |
| EV/EBITDA | -9.2x | XXX | -8.2x | XXX | XXX | XXX |
| EV/EBIT | -7.2x | XXX | -5.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.3x | XXX | -6.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTriSalus Life Sciences's last 12 month revenue growth is 54%
TriSalus Life Sciences's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.6M for the same period.
TriSalus Life Sciences's rule of 40 is -261% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TriSalus Life Sciences's rule of X is 69% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TriSalus Life Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 54% | XXX | 54% | XXX | XXX | XXX |
| EBITDA Margin | -65% | XXX | -89% | XXX | XXX | XXX |
| EBITDA Growth | -67% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -261% | XXX | -35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 88% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 60% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 209% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TriSalus Life Sciences acquired XXX companies to date.
Last acquisition by TriSalus Life Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . TriSalus Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TriSalus Life Sciences founded? | TriSalus Life Sciences was founded in 2020. |
| Where is TriSalus Life Sciences headquartered? | TriSalus Life Sciences is headquartered in United States of America. |
| How many employees does TriSalus Life Sciences have? | As of today, TriSalus Life Sciences has 110 employees. |
| Who is the CEO of TriSalus Life Sciences? | TriSalus Life Sciences's CEO is Ms. Mary T. Szela. |
| Is TriSalus Life Sciences publicy listed? | Yes, TriSalus Life Sciences is a public company listed on NAS. |
| What is the stock symbol of TriSalus Life Sciences? | TriSalus Life Sciences trades under TLSI ticker. |
| When did TriSalus Life Sciences go public? | TriSalus Life Sciences went public in 2023. |
| Who are competitors of TriSalus Life Sciences? | Similar companies to TriSalus Life Sciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of TriSalus Life Sciences? | TriSalus Life Sciences's current market cap is $194M |
| What is the current revenue of TriSalus Life Sciences? | TriSalus Life Sciences's last 12 months revenue is $35.8M. |
| What is the current revenue growth of TriSalus Life Sciences? | TriSalus Life Sciences revenue growth (NTM/LTM) is 54%. |
| What is the current EV/Revenue multiple of TriSalus Life Sciences? | Current revenue multiple of TriSalus Life Sciences is 6.0x. |
| Is TriSalus Life Sciences profitable? | Yes, TriSalus Life Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TriSalus Life Sciences? | TriSalus Life Sciences's last 12 months EBITDA is -$23.3M. |
| What is TriSalus Life Sciences's EBITDA margin? | TriSalus Life Sciences's last 12 months EBITDA margin is -65%. |
| What is the current EV/EBITDA multiple of TriSalus Life Sciences? | Current EBITDA multiple of TriSalus Life Sciences is -9.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
